Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2024 | The mechanism of action of CNM-Au8 and its potential in various neurodegenerative diseases

Michael Barnett, MBBS, FRACP, PhD, Royal Prince Alfred Hospital Sydney, Sydney, Australia, discusses the mechanism of action of the novel therapeutic CNM-Au8. This therapy consists of gold nanocrystals that penetrate neurons and glial cells to promote cellular energetics, and potentially recover cells susceptible to degeneration. Theoretically, it has applications in various neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), as well as multiple sclerosis (MS). This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.